Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

• Published in: Journal of neurology, neurosurgery and psychiatry Vol. 94; no. 1; pp. 1 - 9
• Main Authors: Montalban, Xavier, Wallace, Daniel, Genovese, Mark C, Tomic, Davorka, Parsons-Rich, Dana, Le Bolay, Claire, Kao, Amy H, Guehring, Hans
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01.01.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: Antibodies; Arthritis, Rheumatoid - drug therapy; Autoimmune diseases; Clinical trials; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Humans; IMMUNOLOGY; Lupus; Lupus Erythematosus, Systemic - drug therapy; Multiple Sclerosis; Multiple Sclerosis - drug therapy; Nervous system; Patients; Rheumatoid arthritis; RHEUMATOLOGY; SLE; Streptococcus infections; Treatment Outcome; IMMUNOLOGY; RHEUMATOLOGY; MULTIPLE SCLEROSIS; SLE

ObjectiveAnalyse the integrated safety profile of evobrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), using pooled data from multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) trials.MethodsPhase II, randomised, double-blind, placebo-controlled trial data...